Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ERAS is expected to report earnings to fall 80.93% to -11 cents per share on August 06
Q2'26
Est.
$-0.11
Q1'26
Missed
by $0.49
Q4'25
Beat
by $0.01
Q3'25
Missed
by $0.01
Q2'25
Est.
$-0.12
The last earnings report on May 11 showed earnings per share of -60 cents, missing the estimate of -10 cents. With 1.68M shares outstanding, the current market capitalization sits at 6.63B.